On December 22, 2023, the signing ceremony for the comprehensive deepening of the strategic cooperation agreement between Beijing CytoNiche Biotechnology Co., Ltd. (hereinafter referred to as CytoNiche Biotech) and Guangzhou Dabo Biopharmaceutical Co., Ltd. (hereinafter referred to as Dabo Biopharma) was successfully held in Guangzhou.

Building on the foundation of their collaboration in the development of the 3D TableTrix® microcarrier scale-up preparation process and IND application, both parties will steadily expand the depth and breadth of their cooperation. This includes jointly constructing a 3D cell-scale intelligent manufacturing platform to achieve closed, automated, and scaled clinical trials of stem cell drugs. Additionally, they will expand the 3D microcarrier process technology platform and collaborate on the development and application of 3D microcarrier technology in virus production, gene drug applications, and more.

Dr. Liu Wei , Co-founder & CEO of CytoNiche Biotech, and Professor Huang Wenlin, Founder & Chairman of Dabo Biopharma, as representatives of both parties, officially signed the agreement at Dabo Biopharma's headquarters in Guangzhou, announcing the successful establishment of a deep strategic partnership.

Dr. Tian Shuo, CEO of Dabo Biopharma, Ms. Huang Caihua, Production Director, Mr. Lai Qingyu, Deputy Director of Government Affairs, Mr. Yin Hao, Southern Region Sales Director of CytoNiche Biotech, Mr. Li Benfa, Sales Manager, and Mr. Mi Lai, Sales Manager, attended the ceremony, witnessing the initiation of this collaboration.

[Strong Collaboration to Boost Cell Therapy Industry Development]

Dabo Biopharma has over 20 years of experience in the large-scale development and application of virus vectors and cells, focusing on the development and transformation of innovative drugs such as gene-targeted therapy and cell therapy. With products covering different stages from pre-clinical to Phase I, II, and III, they possess a GMP workshop of 12,000 square meters compliant with EU, FDA, and China NMPA standards, forming a sustainable development pipeline for a series of innovative anti-tumor drugs and immunotherapy products.

CytoNiche Biotech is dedicated to creating an original 3D cell intelligent manufacturing platform based on 3D microcarrier cell culture technology. They have further developed the 3D FloTrix® cell large-scale fully automated preparation process system. CytoNiche Biotech provides comprehensive solutions for customized amplification processes, serving areas such as stem cells, vaccines, gene therapy, and immunotherapy. They have assisted numerous enterprises in establishing fully enclosed automated cell drug production lines, realizing the scalable, automated, standardized, and intelligent production of cell drugs and their derivative products, contributing to the transformation and clinical application of innovative achievements.

The deep strategic cooperation between CytoNiche Biotech and Dabo Biopharma will not only enhance the technological capabilities and market competitiveness of both parties but also positively impact the entire biopharmaceutical industry. The success of this collaboration will lead the promotion and application of three-dimensional cell intelligent manufacturing technology, driving technological innovation across the industry.

[Creating the Future, Driving Innovation in the Biopharmaceutical Industry]

Professor Huang Wenlin stated:

"We have previously used CytoNiche Biotech's 3D microcarrier technology process to complete the IND application for stem cells. We are confident in the future development of CytoNiche Biotech's 3D scale cell manufacturing technology. This collaboration introduces CytoNiche Biotech's brand-new 3D fully enclosed scale cell production line, and we will closely cooperate to achieve the fully closed, automated, and scaled production of stem cell drugs and clinical research. We believe this collaboration will bring more development opportunities for both parties and provide strong support for driving industry change."

Dr. Liu Weibo expressed:

"We are honored to enter into further deep strategic cooperation with Dabo Biopharma. CytoNiche Biotech will provide the necessary technical and process support for Dabo Biopharma through our mature and perfect line of the original 3D cell intelligent manufacturing platform and comprehensive influence in the field of three-dimensional cell culture. We hope that through long-term and comprehensive cooperation, we can set a benchmark for the future application of three-dimensional cell intelligent manufacturing technology in the cell and gene therapy industry."

In the future, both parties will continue to deepen their cooperation, relying on their respective comprehensive strengths to promote technological innovation and industrial applications in the field of biomedicine. They aim to explore broader markets and provide more advanced and effective treatment solutions for global patients.

[About Dabo Biopharma]

Guangzhou Dabo Biopharmaceutical Co., Ltd. was founded by Dr. Huang Wenlin, a national distinguished expert, rotating chairman of the Asia-Pacific Cell and Gene Therapy Association, a special allowance expert of the State Council, outstanding talent in Guangzhou Development Zone (Certificate A), professor at Sun Yat-sen University Cancer Center, and honorary professor at The Chinese University of Hong Kong. The company focuses on the development and transformation of gene engineering technologies such as gene therapy for cancer, immunotherapy, vaccines, and other applications. It is a national high-tech enterprise, and its long-term and unremitting efforts have enabled Dabo Biopharma to establish a sustainable pipeline in the research and development and transformation of gene therapy drugs.

Since its establishment, the company has always focused on technological research and development, forming a relatively complete research and development system. It has established a technical research and development team led by Dr. Huang Wenlin, chief scientist, with most core members holding doctoral degrees. The company has established close cooperative relationships with industry experts and institutions both domestically and internationally.

The company has built an internationally leading gene drug development platform, and its mastery of cutting-edge core technologies has equipped the company with the ability to continuously develop new drugs. As a relying unit, the company has established two provincial-level enterprise key laboratories (engineering laboratories) for the development of anti-tumor drugs and one municipal-level enterprise key laboratory for gene therapy. Supported by these three laboratory platforms, the company has established five new drug research and development functional platforms, including the industrialized production and quality control platform for gene therapy drugs, the research and development and application platform for cell biomedicine, the platform for tumor vaccines and specific immunotherapy products, and the construction and pharmacology platform for anti-tumor lead large molecular candidates.

After years of continuous innovative development, the company has formed a sustainable product line. The product project names include E10A, E10B, E10C, E10D, E10F, E10G, E10H, E10I, E10J, etc., among which

[About CytoNiche]

CytoNiche was established in 2018, led by Professor Yanan Du's research team from the School of Medicine at Tsinghua University, with Tsinghua University as a shareholder. The core technology originated from the transformation of scientific achievements at Tsinghua University and was recognized as a leading technology in "Science and Technology Innovation in China" by the China Association for Science and Technology. As a national-level high-tech enterprise, a national-level specialized and new technology "Little Giant" enterprise, a potential unicorn enterprise, it has also received key research and development special support from the Ministry of Science and Technology.

As an expert in high-quality three-dimensional cell manufacturing, CytoNiche provides a one-stop customized solution for cell scale-up based on 3D microcarriers. The company has built an original 3D cell smart manufacturing platform, achieving large-scale, automated, intelligent, and closed-cell drug and derivative production preparation. This helps global customers establish the most advanced cell drug production lines. After pioneering the production process pipeline for "billion-level" stem cells, the company is accelerating towards "hundred billion-level," dedicating efforts to empower the cell and gene therapy industry with 3D cell scale-up smart manufacturing technology to benefit more patients.